RT Journal Article
SR Electronic
T1 Development of 3-in-1 nanotherapeutic strategies for ovarian cancer
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2024.07.17.604002
DO 10.1101/2024.07.17.604002
A1 Durocher, Emma
A1 McGrath, Sean
A1 Gahunia, Esha
A1 Matsuura, Naomi
A1 Gadde, Suresh
YR 2024
UL http://biorxiv.org/content/early/2024/07/22/2024.07.17.604002.abstract
AB TOC Among gynecological cancers, ovarian cancer causes the most fatality. Platin-based chemotherapy is the primary therapeutic option, but it is limited by a variety of drug resistance mechanisms. Ovarian cancer is a complex and challenging disease to treat, and combination approaches have shown stronger efficacy than a single drug alone. However, they still need to overcome challenges, such as the non-selective distribution of drugs, and side effects caused by each drug in the combination. To overcome these issues, here we explored a 3-in-1 combination nanotherapeutic approach containing cisplatin, olaparib, and metformin for ovarian cancer. To encapsulate hydrophilic cisplatin and metformin inside the nanoparticle (NP) core, we developed cisplatin polymer prodrugs and metformin derivatives. Our results showed successful development of 3-in-1 NPs containing cisplatin, olaparib, and metformin, and they are stable in the physiological conditions. In vitro evaluation showed each agent in the 3-in-1 NPs is active and exerts therapeutic effects, contributing to ovarian cancer cell killing at lower concentrations. These results provide insight into developing novel nanotherapeutic strategies for improving ovarian cancer treatment.Competing Interest StatementThe authors have declared no competing interest.